CCHPS Technical Meeting

July 2026

Speaker Bio

Dr. Daniel De Vries obtained his Batchelor of Science from the United States Military Academy at West Point and then his Master of Science and Ph.D. from the University of Michigan. Dr. De Vries has more than 20 years of hands-on experience working with open sources of α-, β-, and γ-emitting radionuclides in activities ranging from a few nanocuries up to more than 20 Ci. Throughout his career Dr. De Vries has successfully supervised and trained students (undergraduate to Ph.D.) and technicians in “wet” radiochemistry and nuclear chemistry. Dr. De Vries has been working with radioactive materials at NorthStar for more than thirteen years and is currently an Authorized User on multiple NorthStar RAM Licenses. His previous experiences include work at the University of Michigan’s Ford Nuclear Reactor (2MWth) and at the Delft University of Technology’s Hoger Onderwijs Reactor (2MWth), where he was appointed as the first non-Dutch “Chemisch Gemachtigde” or Irradiation Safety Assessor. In this position Dr. De Vries was charged with determining whether sample materials were safe to go into the reactor’s core for irradiation.

NorthStar’s Ac-225 Program: Transforming Legacy Ra-226 to a Cancer-Killing Therapeutic, Free of Long-Lived Impurities

Daniel J. DeVries, Ph.D., Senior Director of Medical Radioisotope Product Development at NorthStar Medical Radioisotopes, LLC will be discussing NorthStar’s groundbreaking technology being used to supply commercial quantities of Ac-225 to the worldwide market. NorthStar is a commercial stage radiopharmaceutical company producing novel therapeutic isotopes such as Cu-67 and Ac-225, as well as providing Contract Development and Manufacturing Organization (CDMO) services co-located on the same campus in Beloit, WI.

NorthStar uses an IBA TT300-HE Rhodotron electron accelerator, which operates at 40 MeV, to produce an intense beam of bremsstrahlung photons. These photons interact with Ra-226, which is hermetically sealed in a small target capsule, to produce Ra-225 via the Ra-226(γ,n) Ra-225 reaction pathway. Sources containing Ra-225 are then periodically processed to harvest no-carrier-added (n.c.a.) Ac-225. Aspects of the target manufacture, irradiation, chemical process, and analytical testing will also be discussed.

NorthStar is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, can detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces Cu-67 and is the first commercial-scale producer of no-carrier added Ac-225 using electron-accelerator technology. The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.

For more information about NorthStar’s comprehensive portfolio and patient-focused services, visit: www.northstarnm.com

Date